Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963

Area of Science:

• Oncology
• Virology
• Gene Therapy

Background:

• Oncolytic viruses (virotherapeutics) offer novel cancer treatment mechanisms.
• Limitations in intravenous delivery and systemic efficacy hinder current virotherapeutics.
• Improved agents are needed to realize the full potential of virotherapy.

Purpose of the Study:

• To rationally design and evaluate a systemically effective oncolytic virotherapeutic (JX-963).
• To engineer a poxvirus for enhanced tumor targeting and immune stimulation.
• To assess the in vitro and in vivo efficacy of JX-963 against various cancers.

Main Methods:

• Identified a potent poxvirus strain with efficient tumor trafficking after intravenous administration.
• Engineered the virus by deleting thymidine kinase and vaccinia growth factor genes for cancer cell targeting (E2F and EGFR activation).
• Further modified the virus to express human GM-CSF for tumor-specific T-lymphocyte induction.

Main Results:

• JX-963 demonstrated potent efficacy across tested cancer cell lines, outperforming Onyx-015 adenovirus and matching wild-type vaccinia.
• Significant cancer selectivity was confirmed in vitro, in vivo (tumor-bearing rabbits), and ex vivo (human surgical samples).
• Intravenous JX-963 achieved systemic efficacy against primary carcinomas and widespread metastases in immunocompetent animal models.

Conclusions:

• JX-963 is a rationally designed, targeted virotherapeutic with potential for systemic cancer treatment.
• The engineered virus exhibits potent anti-cancer activity and selectivity.
• JX-963 warrants further clinical investigation for human cancer therapy.